MAPT and Alzheimer disease: Considering such rapid changes in the clinical circumstances surrounding DS and AD, we defined DS-AD as DS individuals with biomarker changes that suggest the presence of amyloid and tau pathology, and not as individuals with DS who simply show a decline in social life capacities.